Except from First Word Pharma article - link to full article is...

Except from First Word Pharma article - link to full article is below !!

Analysts see at least $400,000 annual price tag

In 2018, Acadia entered into an exclusive license agreement with Neuren Pharmaceuticals to develop the candidate for Rett syndrome and other indications in North America. Acadia noted that with the approval of Daybue, it received a rare paediatric disease priority review voucher. The treatment is expected to be available in the US by the end of April.

The FDA decision comes months after the agency declined to approve expanded use of Acadia's drug Nuplazid (pimavanserin) to treat psychosis related to Alzheimer's disease (see ViewPoints: Investors see Acadia's CRL as clearing event). Industry observers have said approval of Daybue would help drive growth for the company in the near term. "Based on investor feedback, we believe investors expect the list price for [Daybue] at launch to be in the range of $400,000 to $600,000 per year," analysts at Mizuho said in a recent note prior to the approval.

https://firstwordpharma.com/story/5715202